EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety in early application of Ruxolitinib for high-risk acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation

Qian Cheng, Yishu Tang, Feiyang Liu, Xin Li, Dan Fang

Transplant Immunology · 2024

DOI: 10.1016/j.trim.2023.101978 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Immunology, 2024. Verfasst von Qian Cheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Nitriles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been identified as the potentially curative treatment for high-risk acute lymphoblastic leukemia (ALL) in adult patients. However, relapse of the disease and/or development of graft-versus-host disease (GVHD) remain to be the most common barriers for successful allo-HSCT. Preclinical studies showed that ruxolitinib, a Janus tyrosine kinase (Jak)1 and Jak2 inhibitor, has a selective anti-GVHD effects while preserving a potent graft-versus-leukemia (GVL) effect. Our study aimed to investigate the efficacy and safety in early application of ruxolitinib for the high-risk ALL patients to prevent GVHD. METHODS: There were eight patients undergoing allo-HSCT at the Bone Marrow Transplantation Center of the Third Xiangya Hospital of Central South University between April 2020 and April 2021. Ruxolitinib (5-10 mg twice daily) was administered early (median time: 45 days) after stem cell infusion. RESULTS: After a median follow-up of 14 months (range from 8 to 18 months), the ALL disease relapse occurred in two cases. Among all eight patients, two of them developed grade I/II acute (a) GVHD, while no patient developed grade III/IV aGVHD, and one patient developed chronic (c) GVHD. As for the virus activation, no patient developed EBV activation or EBV related lymphoproliferative disease, and three patients developed CMV activation. Our results suggest that the early application of ruxolitinib could safely and effectively prevent the occurrence of GVHD after allo-HSCT for the high-risk ALL patients. However, it may have a limited effect on preventing the recurrence of high-risk ALL and thus may require additional therapy with other anti-relapse drugs. CONCLUSIONS: Our preliminary observations suggest that an early application of ruxolitinib can safely and effectively prevent the occurrence of GVHD after allo-HSCT for the high-risk ALL patients. However, ruxolitinib may have a limited effect on preventing the ALL recurrence of high-risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationGraft vs Host DiseasePrecursor Cell Lymphoblastic Leukemia-LymphomaNitrilesPyrazolesPyrimidinesAdultHumansAcute DiseaseChronic DiseaseRecurrenceRetrospective Studies

Stichwörter der Autor:innen

Efficacy and safetyGVHDHigh-risk acute lymphoblastic leukemiaRuxolitinib

Substanzen

ruxolitinibNitrilesPyrazolesPyrimidines

Autor:innen und Institutionen

  • Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
  • Department of Emergency, The Third Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
  • Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. Electronic address: lixiner1975@163.com.
  • Department of Hematology, Changde Hospital, Xiangya School of Medicine, Central South University (The first people's hospital of Changde city), Changde, Hunan, People's Republic of China. Electronic address: 814112138@q…

Zitieren

APA

Cheng, Q., Tang, Y., Liu, F., Li, X., & Fang, D. (2024). Efficacy and safety in early application of Ruxolitinib for high-risk acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation. Transplant Immunology. https://doi.org/10.1016/j.trim.2023.101978

Vancouver

Cheng Q, Tang Y, Liu F, Li X, Fang D. Efficacy and safety in early application of Ruxolitinib for high-risk acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation. Transplant Immunology. 2024. doi:10.1016/j.trim.2023.101978

BibTeX
@article{Cheng2024,
  author = {Cheng, Qian and Tang, Yishu and Liu, Feiyang and Li, Xin and Fang, Dan},
  title = {Efficacy and safety in early application of Ruxolitinib for high-risk acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation},
  journal = {Transplant Immunology},
  year = {2024},
  doi = {10.1016/j.trim.2023.101978}
}
Kostenlos starten →